1. Home
  2. BIAF vs CMCT Comparison

BIAF vs CMCT Comparison

Compare BIAF & CMCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BIAF
  • CMCT
  • Stock Information
  • Founded
  • BIAF 2014
  • CMCT 1993
  • Country
  • BIAF United States
  • CMCT United States
  • Employees
  • BIAF N/A
  • CMCT N/A
  • Industry
  • BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • CMCT Real Estate Investment Trusts
  • Sector
  • BIAF Health Care
  • CMCT Real Estate
  • Exchange
  • BIAF Nasdaq
  • CMCT Nasdaq
  • Market Cap
  • BIAF 6.7M
  • CMCT 5.5M
  • IPO Year
  • BIAF 2022
  • CMCT N/A
  • Fundamental
  • Price
  • BIAF $1.59
  • CMCT $9.36
  • Analyst Decision
  • BIAF Hold
  • CMCT
  • Analyst Count
  • BIAF 1
  • CMCT 0
  • Target Price
  • BIAF N/A
  • CMCT N/A
  • AVG Volume (30 Days)
  • BIAF 175.0K
  • CMCT 3.2M
  • Earning Date
  • BIAF 11-14-2025
  • CMCT 11-14-2025
  • Dividend Yield
  • BIAF N/A
  • CMCT N/A
  • EPS Growth
  • BIAF N/A
  • CMCT N/A
  • EPS
  • BIAF N/A
  • CMCT N/A
  • Revenue
  • BIAF $6,776,739.00
  • CMCT $114,871,000.00
  • Revenue This Year
  • BIAF N/A
  • CMCT N/A
  • Revenue Next Year
  • BIAF $20.04
  • CMCT N/A
  • P/E Ratio
  • BIAF N/A
  • CMCT N/A
  • Revenue Growth
  • BIAF N/A
  • CMCT N/A
  • 52 Week Low
  • BIAF $1.52
  • CMCT $4.03
  • 52 Week High
  • BIAF $46.53
  • CMCT $79.80
  • Technical
  • Relative Strength Index (RSI)
  • BIAF 34.93
  • CMCT 61.39
  • Support Level
  • BIAF $1.91
  • CMCT $6.55
  • Resistance Level
  • BIAF $2.25
  • CMCT $11.66
  • Average True Range (ATR)
  • BIAF 0.20
  • CMCT 1.55
  • MACD
  • BIAF -0.06
  • CMCT 0.45
  • Stochastic Oscillator
  • BIAF 6.54
  • CMCT 47.45

About BIAF bioAffinity Technologies Inc.

bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.

About CMCT Creative Media & Community Trust Corporation

Creative Media & Community Trust Corp is formed to invest in, own, and operate Class A and creative office investments in improving urban communities throughout the United States. It operates through segments such as office, hotel and multifamily properties and lending. The Office segment includes rental of office space and other tenant services, including tenant reimbursements, parking, and storage space rental. The Hotel segment relates to operations of hotel properties whereas, the lending segment refers to income from the yield and other related fee income earned on its loans receivable. The lending segment includes income recognized from the sale of government guaranteed portion of loans receivable, income from the yield on its loans receivable and other related fee income earned.

Share on Social Networks: